These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10807806)

  • 21. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer.
    Dawe DE; Pond GR; Ellis PM
    Clin Lung Cancer; 2016 Nov; 17(6):563-572.e2. PubMed ID: 27374398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ; Gardner JF; Seal B; Edelman MJ
    J Thorac Oncol; 2011 May; 6(5):934-41. PubMed ID: 21372743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
    Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
    Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.
    Zeliadt SB; Sekaran NK; Hu EY; Slatore CC; Au DH; Backhus L; Wu DY; Crawford J; Lyman GH; Dale DC
    J Thorac Oncol; 2011 Oct; 6(10):1726-32. PubMed ID: 21857253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer.
    Hayman JA; Abrahamse PH; Lakhani I; Earle CC; Katz SJ
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1001-7. PubMed ID: 17689029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
    Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
    Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.
    Ganti AK; Hirsch FR; Wynes MW; Ravelo A; Ramalingam SS; Ionescu-Ittu R; Pivneva I; Borghaei H
    Clin Lung Cancer; 2017 Nov; 18(6):640-650.e2. PubMed ID: 28522158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review.
    Blinman P; Alam M; Duric V; McLachlan SA; Stockler MR
    Lung Cancer; 2010 Aug; 69(2):141-7. PubMed ID: 20570009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Tong KM; Laskin J; Ho C
    Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.